New clinical trial partnership to help LEO Pharma move at pace

10 March 2023

Danish dermatology specialist LEO Pharma has inked a strategic partnership with Irish firm ICON (Nasdaq: ICLR), related to clinical trial execution.

LEO said the deal would allow it to scale up its clinical trial operations in a way that is “patient-centric and cost effective,” while supporting an ambition to create “the most effective and efficient clinical portfolio execution organizations in the industry.”

The firm is riding high at the moment, after announcing more positive results for delgocitinib, from the DELTA 2 trial, the second of two Phase III studies testing the novel hand eczema candidate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK